In vitro and in silico assessment of urea/thiourea derivatives in antimicrobial therapy by Gajdács, Márió et al.
 Magyar Kémikusok Egyesülete Csongrád Megyei 
Csoportja és a Magyar Kémikusok Egyesülete 
rendezvénye 
 
 
 
XL. 
KÉMIAI ELŐADÓI NAPOK 
 
 
 
 
 
 
 
 
 
 
 
 
 
Szegedi Akadémiai Bizottság Székháza 
Szeged, 2017. október 16-18. 
 
  
 
2 
 
 
 
 
 
Szerkesztették: 
 
 
Ádám Anna Adél, 
Timár Zita 
 
SZTE TTIK Szerves Kémia Tanszék 
 
 
Ziegenheim Szilveszter 
 
SZTE TTIK Szervetlen és Analitikai Kémia Tanszék 
 
 
 
 
 
 
 
 
 
ISBN 978-963-9970-83-0 
 
 
 
116 
 
IN VITRO AND IN SILICO ASSESSMENT OF UREA/THIOUREA 
DERIVATIVES IN ANTIMICROBIAL THERAPY 
 
Márió Gajdács1, Tímea Mosolygó1, Edit Urbán2, Dorota Łażewska3, Jadwiga 
Handzlik
3, Katarzyna Kieć-Kononowicz3, Enrique Domínguez-Álvarez4, 
Gabriella Spengler
1
 
 
1
University of Szeged, Faculty of Medicine, Department of Medical Microbiology and 
Immunobiology, 6720 Szeged, Dóm square 10.  
2
University of Szeged, Faculty of Medicine, Department of Clinical Microbiology, 6725 
Szeged, Semmelweis street 6. 
3
Jagiellonian University Medical College, Faculty of Pharmacy, Department of Technology 
and Biotechnology of Drugs, 30-688 Kraków, Medyczna 9. 
4
Spanish National Research Council, Institute of Organic Chemistry, 28006 Madrid, Juan 
de la Cierva 3. 
 
The emergence and spread of antimicrobial resistance, together with the lack of 
newly developed antimicrobial drugs present serious public health issues worldwide. Apart 
from bacteria that do not respond to antibiotics, therapy-resistant mutants of viruses and 
multidrug resistant fungal strains introduce additional difficulties to effective therapy.
[1]
 
Novel antimicrobial compounds containing chalcogenic elements (S, Se, Te) have attracted 
reasonable attention in the field of experimental chemotherapy.
[2]
 
The aim of our study was to evaluate the potency of novel urea and thiourea 
derivatives (1-10) against various microorganisms (aerobic and anaerobic bacteria, fungi, 
Herpes Simplex Virus 1) in vitro, as well as their conformity to the attributes of successful 
drug candidates, using computational in silico methods. 
 
Figure 1.: General structure of the tested compounds 
 
 
The antimicrobial activities of the tested compounds against reference strains of 
aerobic or anaerobic bacteria and yeasts were evaluated using disk diffusion tests and when 
warranted, broth microdilution method, according to EUCAST standards.
[3]
 A double-disk 
synergy test was used for the detection of synergism between the derivatives and antibiotics 
(ampicillin, cefuroxime, imipenem, vancomycin) against multiresistant bacterial strains.
[4]
 
A MIC reduction assay was performed to quantify the effects of the (thio)ureas on the 
minimal inhibitory concentrations of reference drugs. The anti-HSV activity of the tested 
compounds was evaluated using MTT assay on Vero cells.
[5]
 The predicted 
physicochemical and pharmacokinetic properties of the tested compounds were determined 
in silico, using OSIRIS Molecular Property Explorer and PreADMET software.
[6,7]
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Table 1.: Bacterial and fungal reference strains used in our experiments 
Bacteria Fungi 
Aerobic Anaerobic Multiresistant  
Staphylococcus aureus 
ATCC 25923 
Clostridium perfringens 
ATCC 13124 
Staphylococcus aureus  
ATCC 43300 (MRSA) 
Candida albicans  
ATCC 10231 
Staphylococcus 
epidermidis ATCC 12228 
Propionibacterium acnes 
ATCC 11827 
Enterococcus faecium 
QC/2008/12/03 (VRE) 
Candida krusei  
ATCC 14243 
Enterococcus faecalis 
ATCC 29212 
Bacteroides fragilis 
ATCC 25285 
Acinetobacter baumanii 
clin. isol. no.: 59738 
Candida glabrata  
ATCC 2001 
Escherichia coli  
ATCC 25922 
 Pseudomonas aeruginosa 
ATCC 27863 
Candida parapsilosis 
ATCC 22019 
Klebsiella pneumoniae 
ATCC 49619 
  Candida tropicalis  
ATCC 13803 
Proteus mirabilis  
PMI 60007 
  Cryptococcus diffluens 
ATCC 32059 
Salmonella Derby 
HWCMB 10032 
   
Pseudomonas aeruginosa 
PAE 170022 
   
 
The ureas/thioureas did not show antibacterial activity against the aerobic and 
anaerobic bacteria, nor did they inhibit the growth of the fungal strains included in our 
study (MICs of the tested compounds were >200 µM; inhibition zone diameters <10 mm in 
all experiments). Some of the tested compounds presented modest adjuvant properties, 
reducing the inhibitory concentrations of antibiotics by 25-50% against susceptible bacteria, 
however they did not influence the effects of reference drugs against resistant strains. Based 
on the percentages of maximum cell recovery and selectivity, a 4-nitrophenyl-derivative 
and a 1,4-phenylene-substituted compound showed potent anti-HSV properties. All tested 
compounds complied with Lipinsky’s Rule of Five and the predicted percentages of 
intestinal absorption are excellent (≥ 95%) for all the respective compounds.[8,9] 
The tested thio(ureas) lacked any antimicrobial activity against the bacterial and 
fungal strains, and their potential as antibiotic adjuvants is modest at best. On the other 
hand, their predicted ADME properties are of the highest standard and some of the 
compound showed promising antiviral activity. The synthesis and biological evaluation of 
novel derivatives in the future could introduce alternative antiviral drugs with selective 
activity. 
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